Relay Doubles the Bar, Outpacing Novartis with a 60% Response in Rare Disease

Why It Matters

The breakthrough response rate reshapes the therapeutic landscape for rare vascular anomalies and positions Relay for fast‑track regulatory review, potentially delivering the first effective oral option for these patients.

Key Takeaways

• Zovegalisib achieved 60% volumetric response in Phase 2 trial
• Response rate beats 20‑25% benchmark and Novartis’ 11%
• No dose discontinuations; only 9% experienced grade 3+ adverse events
• FDA accelerated approval pathway being pursued for the oral inhibitor
• Expansion cohorts added at 400 mg daily and 300 mg twice daily

Pulse Analysis

Vascular malformations, a collection of rare disorders driven by abnormal vessel growth, have long lacked targeted oral therapies. The PI3Kα pathway, mutated in the PROS spectrum, offers a mechanistic foothold, and Relay’s mutant‑selective inhibitor zovegalisib is the first candidate to translate that biology into meaningful tumor shrinkage. By enrolling both adults and adolescents, the Phase 2 ReInspire study demonstrates that precise inhibition can achieve rapid volumetric reductions, a critical metric for patients whose disease burden often translates into pain, functional impairment, and disfigurement.

The trial’s 60% overall response rate not only doubles the historic 20‑25% success bar set by analysts but also eclipses Novartis’ 11% outcome with Vijoice, a competing PI3K inhibitor that faltered in a similar PROS cohort. Safety data reinforce the drug’s promise: only two patients experienced grade 3 or higher treatment‑related events, and there were no discontinuations despite dose escalation up to 300 mg twice daily. Such a tolerability profile aligns with expectations for mutant‑selective agents and bolsters Relay’s case for the FDA’s accelerated approval pathway, which rewards therapies addressing serious unmet needs with compelling early efficacy.

Investors have reacted sharply, with Relay’s shares climbing roughly 9% to $13.29 after the data release. The company’s next steps include opening expansion cohorts at 400 mg once daily and 300 mg twice daily, as well as a pediatric dose‑finding study for children aged six to 11. Beyond rare disease, zovegalisib is advancing in metastatic breast cancer trials, suggesting a broader oncology footprint that could further amplify its commercial upside and solidify Relay’s position as a leader in precision‑targeted PI3Kα therapeutics.